Vaccinex (VCNX) Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VCNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vaccinex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$1.35 |
| 52 Week Low | US$0.25 |
| Beta | 0.73 |
| 1 Month Change | 98.77% |
| 3 Month Change | 138.48% |
| 1 Year Change | 6.89% |
| 3 Year Change | -99.13% |
| 5 Year Change | -99.79% |
| Change since IPO | -99.90% |
Recent News & Updates
Shareholder Returns
| VCNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 24.5% | -1.4% | 0.2% |
| 1Y | 6.9% | 27.9% | 16.9% |
Return vs Industry: VCNX underperformed the US Biotechs industry which returned 28.4% over the past year.
Return vs Market: VCNX underperformed the US Market which returned 18.7% over the past year.
Price Volatility
| VCNX volatility | |
|---|---|
| VCNX Average Weekly Movement | 50.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VCNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VCNX's weekly volatility has increased from 43% to 50% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 25 | Maurice Zauderer | www.vaccinex.com |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer’s disease and has completed phase 2 study for the treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer.
Vaccinex, Inc. Fundamentals Summary
| VCNX fundamental statistics | |
|---|---|
| Market cap | US$3.01m |
| Earnings (TTM) | -US$18.63m |
| Revenue (TTM) | US$601.00k |
Is VCNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCNX income statement (TTM) | |
|---|---|
| Revenue | US$601.00k |
| Cost of Revenue | US$12.55m |
| Gross Profit | -US$11.94m |
| Other Expenses | US$6.69m |
| Earnings | -US$18.63m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.96 |
| Gross Margin | -1,987.35% |
| Net Profit Margin | -3,100.50% |
| Debt/Equity Ratio | -1.0% |
How did VCNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/14 15:31 |
| End of Day Share Price | 2026/01/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaccinex, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Matthew Kaplan | Ladenburg Thalmann & Company |
| Leland Gershell | Oppenheimer & Co. Inc. |